



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

9 July 2020

DEPARTMENT MEMORANDUM

No. 2020 – 0305

TO : **DIRECTORS OF CENTERS FOR HEALTH DEVELOPMENT (CHDs), CHIEFS OF MEDICAL CENTERS, HOSPITALS, SANITARIA, EXECUTIVE DIRECTORS OF SPECIALTY HOSPITALS, MINISTER OF HEALTH – BANGSAMORO AUTONOMOUS REGION IN MUSLIM MINDANAO (MOH-BARMM), LOCAL GOVERNMENT UNITS (LGU) HEALTH FACILITIES AND OTHER CONCERNED**

SUBJECT : **PRICE ADJUSTMENTS OF MEDICINES IN THE 2019 EDITION OF THE DRUG PRICE REFERENCE INDEX (DPRI) PLACED UNDER EXECUTIVE ORDER NO. 104**

In relation to the newly signed Executive Order (EO) No. 104 entitled “*Improving Access to Healthcare through the Regulation of Prices in the Retail of Drugs and Medicine.*” wherein 87 drugs molecules (equivalent to 133 preparation/formulas) were placed under the Maximum Retail Price (MRP) and Maximum Wholesale Price (MWP), adjustment/amendment of the current 2019 Drug Price Reference Index (DPRI) is considered necessary.

Hence, the prices of the following medicines with previous 2019 DPRI were adjusted accordingly. Likewise, essential medicines under EO No. 104 not part of the 2019 DPRI were included in the latter. Adjusted 2019 DPRI was derived based on MWP plus Value-Added-Tax (VAT):

Drug Name	2019 DPRI (Old)	2019 DPRI (with 10% inflation)	MWP (VAT exclusive)	Adjusted 2019 DPRI MWP (VAT inclusive)
Medicines with Previous 2019 DPRI				
Beractant 25 mg/mL, 8 mL vial	17,811.36	19,592.50	14,086.19	15,776.53
Deferoxamine 500 mg vial	343.50	377.85	163.68	183.32
Morphine (as sulfate) 10 mg MR tablet	20.00	22.00	10.08	11.29
Morphine (as sulfate) 30 mg MR tablet	71.79	72.89	26.18	29.32
Nimodipine 30 mg Tablet	36.00	39.60	27.52	30.82
Oxycodone (as hydrochloride) 10 mg tablet	127.16	139.88	115.69	129.75
Oxycodone (as hydrochloride) 10 mg/mL, 1 mL ampule for IV infusion	1,019.70	1,121.67	552.40	618.69

Drug Name	2019 DPRI (Old)	2019 DPRI (with 10% inflation)	MWP (VAT exclusive)	Adjusted 2019 DPRI MWP (VAT inclusive)
Oxycodone (as hydrochloride) 10 mg/mL, 2 mL ampule for IV infusion	1,019.70	1,121.67	923.50	1,034.32
Oxycodone (as hydrochloride) + Naloxone (as hydrochloride) 5 mg + 2.5 mg tablet prolonged release	113.94	-	80.10	89.71
Rituximab 10 mg/mL, 50 mL vial	82,127.48	-	47,673.39	53,394.20
Sevelamer Carbonate 800 mg tablet	65.63	-	34.63	38.79
Sirolimus 1 mg tablet	275.00	302.50	185.72	208.01
Tinzaparin (as sodium) 10,000 anti-XA IU, 2 mL vial	1,414.62	1,556.08	711.57	796.96
Trastuzumab 150 mg lyophilized Powder	38,272.00	42,099.20	26,025.24	29,148.27
Medicines without Previous 2019 DPRI				
Azathioprine 50 mg tablet	-	-	34.30	38.42
Basiliximab 20 mg vial	-	-	53,969.49	60,445.83
Ciclosporin 100 mg/mL solution, 50 mL	-	-	6,634.84	7,431.02
Formoterol 12 mcg dry powder for inhalation	-	-	15.32	17.16
Ganciclovir (as sodium) 500 mg vial	-	-	1,630.78	1,826.47
Goserelin (as acetate) 3.6 mg depot solution, pre-filled syringe	-	-	4,118.80	4,613.06
Goserelin (as acetate) 10.8 mg depot solution, pre-filled syringe	-	-	14,077.89	15,767.24
Human Recombinant Tissue Type Plasminogen-Activator (Alteplase) 50 mg powder	-	-	27,264.30	30,536.02
Immunoglobulin, Antithymocyte (ATG) (rabbit) 25 mg/5 mL vial	-	-	11,704.12	13,108.61
Morphine (as sulfate) 60 mg MR tablet	-	-	69.67	78.03
Mycophenolic Acid (as Mycophenolate Sodium) 360 mg tablet	-	-	58.71	65.76
Oxycodone (as hydrochloride) + Naloxone (as hydrochloride) 10 mg + 5 mg prolonged-released tablet	-	-	72.92	81.67
Oxycodone (as hydrochloride) + Naloxone (as hydrochloride) 20 mg + 10 mg prolonged-release tablet	-	-	143.80	161.06

Drug Name	2019 DPRI (Old)	2019 DPRI (with 10% inflation)	MWP (VAT exclusive)	Adjusted 2019 DPRI MWP (VAT inclusive)
Oxycodone (as hydrochloride) + Naloxone (as hydrochloride) 40 mg + 20 mg prolonged-release tablet	-	-	243.54	272.76
Rituximab 10 mg/mL, 10 mL vial	-	-	9,783.74	10,957.79
Sirolimus 0.5 mg tablet	-	-	136.97	153.41
Tacrolimus 1 mg slow-release capsules	-	-	83.18	93.16
Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe	-	-	238.31	266.91
Tiotropium (as bromide) 18 mcg/dose with appropriate accompanying dispenser	-	-	57.33	64.21

Likewise, adding an allowable margin for up to 10% to account for inflation shall no longer be applicable for the abovementioned medicines.

Further, the Highest Price Range (HPR) flexibility pursuant to DM No. 2020-0193 dated 17 April 2020 entitled "*Guidelines on the Utilization of the Maximum Price in the Range Used in the Calculation of the 2019 Drug Price Reference Index (DPRI) for All Drugs and Medicines,*" is hereby repealed. Nevertheless, Geographically Isolated and Disadvantaged Areas (GIDA) may still use the said HPR for their procurement pursuant to Administrative Order No. 2019-0040 dated 14 October 2019 with the subject "*Revised Guidelines in the Implementation of the Philippine Drug Price Reference Index (DPRI) to all Public Hospitals and Health Facilities.*"

Likewise, HPR flexibility for GIDA of the below medicine was also adjusted:

Drug Name	2019 DPRI	2019 DPRI (with 10% inflation)	HPR Flexibility for GIDA (Old)	MWP (VAT exclusive)	Adjusted HPR Flexibility for GIDA MWP (VAT inclusive)
Isosorbide Dinitrate 1 mg/mL, 10 mL ampule	131.78	144.96	1,800.00	485.72	544.01


Moreover, Department Memorandum No. 2019 - 0388 dated October 4, 2019 with the subject "*Availability of the 2019 Drug Price Reference Index (DPRI) Electronic or Soft Copy*" shall no longer be applicable for the aforementioned medicines. Medicines under this issuance shall be applied for both **existing contracts** and succeeding procurements. Therefore, existing contracts with the awarded or procurement prices exceeding the adjusted 2019 DPRI shall be terminated pursuant to existing rules and regulations.

Department Memorandum (DM) No. 2020-0265 dated June 1, 2020 entitled "*Price Adjustment of the 2019 Edition of the Drug Price Reference Index (DPRI)*" is hereby repealed.

All CHDs and MOH-BARMM are hereby directed to disseminate the information to all Provincial Hospitals, Municipal Hospitals, City Hospitals, and Local Government Units and extend necessary assistance therefor.

For strict and prompt compliance.

By Authority of the Secretary of Health:


MARIA ROSARIO SINGH-VERGEIRE MD, MPH, CESO IV
OIC – Undersecretary of Health
Health Regulation Team